11.01.2013 - Researches have constructed the first molecular machine that can produce peptides of defined sequences in milligram quantities.
The group of Bartosz Lewandowski from University of Manchester have taken another step toward the creation of a synthetic machine that performs the duties of a ribosome, which builds proteins in living organisms by joining amino acids together. As reported in Science, they have designed an artificial small-molecule machine that travels along a molecular strand, picking up amino acids that block its path, to synthesise a peptide in a sequence-specific manner.
The chemical structure is based on a rotaxane, a molecular ring threaded onto a molecular axle. The ring carries a thiolate group that iteratively removes amino acids in order from the strand and transfers them to a peptide-elongation site through native chemical ligation. The synthesis was demonstrated with ~1018 molecular machines acting in parallel; this process generated milligram quantities of a peptide with a single sequence confirmed by tandem mass spectrometry.
The study demonstrates that, in principle, small artificial molecular machines can be designed to perform such tasks autonomously. However, their machine lacked performance. In the current lab setting it only joined 3 amino acids together.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.
24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.
20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.
08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.